CD28 and melanoma: Hence, if IFN really abets the generation of CD28 abs, and the latter cause immune suppressive effects by stimulation of T regs or blocking of the CD28 receptor in its proper function, the continuation of IFN-therapies should be critically reconsidered in melanoma patients who develop CD28 abs.